vmireavizВестник медицинского института «РЕАВИЗ». Реабилитация, Врач и ЗдоровьеBulletin of the Medical Institute "REAVIZ" (REHABILITATION, DOCTOR AND HEALTH)2226-762X2782-1579РЕАВИЗ10.20340/vmi-rvz.2021.5.COVID.3vmireaviz-335Research ArticleНовая коронавирусная инфекция COVID-19Novel coronavirus infection COVID-19Влияние типов интерферонов на профилактику и лечение COVID-19Influence of interferon types on COVID-19 prevention and treatmenthttps://orcid.org/0000-0001-8986-9658СаидовС. С.SaidovS. S.

Саидов Саидмурод Саидович - доктор медицинских наук, профессор, проректор по учебной и клинической работе Москва

Moscow

https://orcid.org/0000-0002-6378-6974ИоновС. Н.IonovS. N.

Ионов Станислав Николаевич - профессор кафедры внутренних болезней Москва

Moscow

https://orcid.org/0000-0003-4147-5945СаидовА. С.SaidovA. S.

Саидов Аюбджон Саидович - кандидат медицинских наук, доцент кафедры хирургических болезней Москва

Moscow

https://orcid.org/0000-0002-9674-8384КрасовскаяЛ. В.KrasovskayaL. V.

Красовская Людмила Владимировна - кандидат технических наук, доцент, доцент кафедры естественнонаучных дисциплин Москва

Moscow

https://orcid.org/0000-0002-2575-1551ЗаботновА. В.ZabotnovA. V.

Заботнов Алексей Владимирович - студент 5 курса лечебного факультета Москва

Moscow

Медицинский университет «Реавиз»РоссияMedical University "Reaviz"Russian Federation2021141020211151722Copyright © Саидов С.С., Ионов С.Н., Саидов А.С., Красовская Л.В., Заботнов А.В., 20212021Саидов С.С., Ионов С.Н., Саидов А.С., Красовская Л.В., Заботнов А.В.Saidov S.S., Ionov S.N., Saidov A.S., Krasovskaya L.V., Zabotnov A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vestnik.reaviz.ru/jour/article/view/335

Рассматриваются свойства эндогенного и экзогенного интерферона, как наиболее эффективного элемента борьбы с новой коронавирусной инфекцией, анализируется использование различных групп интерферонов, временные критерии их применения, резистентность к измененным штаммам коронавируса.

This article discusses the properties of endogenous and exogenous interferon as the most effective element in the fight against a new coronavirus infection, analyzes the use of various groups of interferons, the time criteria for their use, and resistance to modified strains of coronavirus.

интерферон (ИНФ)пандемиякоронавирусSARS-CoV-2COVID-19interferon (INF)pandemiccoronavirusSARS-CoV-2COVID-19Исследование проводилось без спонсорской поддержкиReferencesShokri S, Mahmoudvand S, Taherkhani R, Farshadpour F. Modulation of the immune response by Middle East respiratory syndrome coronavirus. J. Cell. Physiol. 2019;234(3):2143-51. https://doi.org/10.1002/jcp.27155Shokri S, Mahmoudvand S, Taherkhani R, Farshadpour F. Modulation of the immune response by Middle East respiratory syndrome coronavirus. J. Cell. Physiol. 2019;234(3):2143-51. https://doi.org/10.1002/jcp.27155Narovlyanskiy A.N. Classification and mechanisms of interferon Actions. In: Ershov F.I., ed. Jubilee Collection «Interferon – 50 Years» [Yubileynyy sbornik «Interferonu – 50 let»]. Moscow. 2007:44-50. (in Russ).Narovlyanskiy A.N. Classification and mechanisms of interferon Actions. In: Ershov F.I., ed. Jubilee Collection «Interferon – 50 Years» [Yubileynyy sbornik «Interferonu – 50 let»]. Moscow. 2007:44-50. (in Russ).Busnadiego I, Fernbach S, Pohl MO, Karakus U, Huber M, Trkola A et al. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2. mBio. 2020,Sep.10;11(5): e01928-20. https://doi.org/10.1128/mBio.01928-20 PMID: 32913009; PMCID: PMC7484541. https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/32913009/Busnadiego I, Fernbach S, Pohl MO, Karakus U, Huber M, Trkola A et al. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2. mBio. 2020,Sep.10;11(5): e01928-20. https://doi.org/10.1128/mBio.01928-20 PMID: 32913009; PMCID: PMC7484541. https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/32913009/Vanderheiden A, Ralfs P, Chirkova T et al. Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures. J Virol. 2020,Sep.15;94(19): e00985-20. https://doi.org/10.1128/JVI.00985-20 PMID: 32699094; PMCID: PMC7495371. https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/32699094/Vanderheiden A, Ralfs P, Chirkova T et al. Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures. J Virol. 2020,Sep.15;94(19): e00985-20. https://doi.org/10.1128/JVI.00985-20 PMID: 32699094; PMCID: PMC7495371. https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/32699094/Zhongji Meng, Tongyu Wang, Li Chen et al. An experimental trial of recombinant human interferon alpha nasal drops to prevent COVID-19 in medical staff in an epidemic area. https://doi.org/10.1101/2020.04.11.20061473Zhongji Meng, Tongyu Wang, Li Chen et al. An experimental trial of recombinant human interferon alpha nasal drops to prevent COVID-19 in medical staff in an epidemic area. https://doi.org/10.1101/2020.04.11.20061473Felgenhauer U, Schoen A, Gad HH et al. Inhibition of SARS-CoV-2 by type I and type III interferons. J Biol Chem. 2020,Oct.9;295(41):13958-13964. https://doi.org/10.1074/jbc.AC120.013788. Epub 2020 Jun 25. PMID: 32587093; PMCID: PMC7549028. https://pubmed.ncbi.nlm.nih.gov/32587093/Felgenhauer U, Schoen A, Gad HH et al. Inhibition of SARS-CoV-2 by type I and type III interferons. J Biol Chem. 2020,Oct.9;295(41):13958-13964. https://doi.org/10.1074/jbc.AC120.013788. Epub 2020 Jun 25. PMID: 32587093; PMCID: PMC7549028. https://pubmed.ncbi.nlm.nih.gov/32587093/Pereda R, Gonzбlez D, Rivero HB et al. Therapeutic Effectiveness of Interferon-α2b Against COVID-19: The Cuban Experience. J Interferon Cytokine Res. 2020, Sep;40(9):438-442. https://doi.org/10.1089/jir.2020.0124. PMID: 32960147. https://www.liebertpub.com/doi/10.1089/jir.2020.0124?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmedPereda R, Gonzбlez D, Rivero HB et al. Therapeutic Effectiveness of Interferon-α2b Against COVID-19: The Cuban Experience. J Interferon Cytokine Res. 2020, Sep;40(9):438-442. https://doi.org/10.1089/jir.2020.0124. PMID: 32960147. https://www.liebertpub.com/doi/10.1089/jir.2020.0124?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmedMordyk A.V., Ivanova O.G., Samsonov K.Yu. et al. Interferon alpha-2b in comprehensive treatment of patients with COVID-19. Infekc. bolezni (Infectious diseases). 2021;19(1):16-25. (In Russ). https://doi.org/10.20953/1729-9225-2021-1-16-25Mordyk A.V., Ivanova O.G., Samsonov K.Yu. et al. Interferon alpha-2b in comprehensive treatment of patients with COVID-19. Infekc. bolezni (Infectious diseases). 2021;19(1):16-25. (In Russ). https://doi.org/10.20953/1729-9225-2021-1-16-25Wang N, Zhan Y, Zhu L et al. Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients. Cell Host Microbe. 2020, Sep. 9;28(3):455-464.e2. https://doi.org/10.1016/j.chom.2020.07.005 Epub 2020 Jul 18. PMID: 32707096; PMCID: PMC7368656. https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/32707096/Wang N, Zhan Y, Zhu L et al. Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients. Cell Host Microbe. 2020, Sep. 9;28(3):455-464.e2. https://doi.org/10.1016/j.chom.2020.07.005 Epub 2020 Jul 18. PMID: 32707096; PMCID: PMC7368656. https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/32707096/Guo K, Barrett BS, Mickens KL, Hasenkrug KJ, Santiago ML. Interferon Resistance of Emerging SARS-CoV-2 Variants. bioRxiv [Preprint]. 2021, Mar.21:2021.03.20.436257. https://doi.org/10.1101/2021.03.20.436257 PMID: 33758840; PMCID: PMC7986999. https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/33758840/Guo K, Barrett BS, Mickens KL, Hasenkrug KJ, Santiago ML. Interferon Resistance of Emerging SARS-CoV-2 Variants. bioRxiv [Preprint]. 2021, Mar.21:2021.03.20.436257. https://doi.org/10.1101/2021.03.20.436257 PMID: 33758840; PMCID: PMC7986999. https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/33758840/

The authors declare that there are no conflicts of interest present.